Clear Search

Showing 2 results for “Ge L” published 2023.

November 2023

Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial

Circulation. 2023; online ahead of print DOI: 10.1161/CIRCULATIONAHA.122.063460

A proof-of-concept trial showed that inclisiran, a small interfering RNA that prevents production of the hepatic PCSK9 protein, could lead to durable reductions in LDL-C levels when added to statins and ezetimibe in 3 out of 4 patients with homozygous familial hypercholesterolaemia (HoFH).

more…

Keywords:

May 2023

Benefits and Harms of Drug Treatment for Type 2 Diabetes: Systematic Review and Network Meta-Analysis of Randomised Controlled Trials

BMJ 2023;381:e074068 DOI 10.1136/bmj-2022-074068

Keeping abreast of the rising volume of randomized trials in adults with type 2 diabetes presents a formidable task. Recent randomized trials have shown cardiovascular and kidney advantages with finerenone, an innovative non-steroidal mineralocorticoid receptor antagonist, and weight loss with tirzepatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GLP-1) receptor agonist.

more…